LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics

Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflammation, atherogenesis, and thrombosis. Approximately 20% of th...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Annual review of pharmacology and toxicology Ročník 64; s. 135
Hlavní autori: Tasdighi, Erfan, Adhikari, Rishav, Almaadawy, Omar, Leucker, Thorsten M, Blaha, Michael J
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 23.01.2024
Predmet:
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - genetics
Cholesterol, LDL - metabolism
Cholesterol, LDL - therapeutic use
Heart Disease Risk Factors
Humans
Lipoprotein(a) - genetics
Lipoprotein(a) - metabolism
Lipoprotein(a) - therapeutic use
Risk Factors
atherosclerosis
clinical trial
cardiovascular disease
lipoprotein(a)
therapy
antisense oligonucleotides
ISSN:1545-4304, 1545-4304
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflammation, atherogenesis, and thrombosis. Approximately 20% of the world's population has increased Lp(a) levels, determined predominantly by genetics. Current clinical practices for the management of dyslipidemia are ineffective in lowering Lp(a) levels. Evolving RNA-based therapeutics, such as the antisense oligonucleotide pelacarsen and small interfering RNA olpasiran, have shown promising results in reducing Lp(a) levels. Phase III pivotal cardiovascular outcome trials [Lp(a)HORIZON and OCEAN(a)] are ongoing to evaluate their efficacy in secondary prevention of major cardiovascular events in patients with elevated Lp(a). The future of cardiovascular residual risk reduction may transition to a personalized approach where further lowering of either LDL-C, triglycerides, or Lp(a) is selected after high-intensity statin therapy based on the individual risk profile and preferences of each patient.
AbstractList Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflammation, atherogenesis, and thrombosis. Approximately 20% of the world's population has increased Lp(a) levels, determined predominantly by genetics. Current clinical practices for the management of dyslipidemia are ineffective in lowering Lp(a) levels. Evolving RNA-based therapeutics, such as the antisense oligonucleotide pelacarsen and small interfering RNA olpasiran, have shown promising results in reducing Lp(a) levels. Phase III pivotal cardiovascular outcome trials [Lp(a)HORIZON and OCEAN(a)] are ongoing to evaluate their efficacy in secondary prevention of major cardiovascular events in patients with elevated Lp(a). The future of cardiovascular residual risk reduction may transition to a personalized approach where further lowering of either LDL-C, triglycerides, or Lp(a) is selected after high-intensity statin therapy based on the individual risk profile and preferences of each patient.
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflammation, atherogenesis, and thrombosis. Approximately 20% of the world's population has increased Lp(a) levels, determined predominantly by genetics. Current clinical practices for the management of dyslipidemia are ineffective in lowering Lp(a) levels. Evolving RNA-based therapeutics, such as the antisense oligonucleotide pelacarsen and small interfering RNA olpasiran, have shown promising results in reducing Lp(a) levels. Phase III pivotal cardiovascular outcome trials [Lp(a)HORIZON and OCEAN(a)] are ongoing to evaluate their efficacy in secondary prevention of major cardiovascular events in patients with elevated Lp(a). The future of cardiovascular residual risk reduction may transition to a personalized approach where further lowering of either LDL-C, triglycerides, or Lp(a) is selected after high-intensity statin therapy based on the individual risk profile and preferences of each patient.Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflammation, atherogenesis, and thrombosis. Approximately 20% of the world's population has increased Lp(a) levels, determined predominantly by genetics. Current clinical practices for the management of dyslipidemia are ineffective in lowering Lp(a) levels. Evolving RNA-based therapeutics, such as the antisense oligonucleotide pelacarsen and small interfering RNA olpasiran, have shown promising results in reducing Lp(a) levels. Phase III pivotal cardiovascular outcome trials [Lp(a)HORIZON and OCEAN(a)] are ongoing to evaluate their efficacy in secondary prevention of major cardiovascular events in patients with elevated Lp(a). The future of cardiovascular residual risk reduction may transition to a personalized approach where further lowering of either LDL-C, triglycerides, or Lp(a) is selected after high-intensity statin therapy based on the individual risk profile and preferences of each patient.
Author Leucker, Thorsten M
Blaha, Michael J
Adhikari, Rishav
Almaadawy, Omar
Tasdighi, Erfan
Author_xml – sequence: 1
  givenname: Erfan
  surname: Tasdighi
  fullname: Tasdighi, Erfan
  email: mblaha1@jhmi.edu
  organization: Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
– sequence: 2
  givenname: Rishav
  surname: Adhikari
  fullname: Adhikari, Rishav
  organization: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
– sequence: 3
  givenname: Omar
  surname: Almaadawy
  fullname: Almaadawy, Omar
  organization: Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA
– sequence: 4
  givenname: Thorsten M
  surname: Leucker
  fullname: Leucker, Thorsten M
  organization: Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
– sequence: 5
  givenname: Michael J
  surname: Blaha
  fullname: Blaha, Michael J
  email: mblaha1@jhmi.edu
  organization: Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37506332$$D View this record in MEDLINE/PubMed
BookMark eNpNkFtLw0AUhBep2Iv-BcmTVGh0z-7mUt9KqVUoKNo-h5Pdkzaam7tJ0X9vxQo-zTzMfAMzZL2qroixK-A3ACq8xarqLO39Zoe2bOtPn0vgQvrAecinJ2wAgQp8Jbnq_fN9NnTujXM-lQrOWF9GAQ-lFAO2WT2P8frOe21tp9sDeuItqaI2127izZyrdY4tGW-O1uT1Hp3uCrTeS-7eJx5WxluUZLd5tfXWO7LYUPdTPWenGRaOLo46Ypv7xXr-4K-elo_z2cpHpWTrQwqhSYUJDMRGxhGHGKdkBDciBohBCCU1ZWEqIIw0xywWgkJOEMUR6gzEiI1_uY2tPzpybVLmTlNRYEV15xIRB4ehIAjlIXp5jHZpSSZpbF6i_Ur-rhDfP5pmog
CitedBy_id crossref_primary_10_1186_s43044_025_00635_1
crossref_primary_10_1016_j_atherosclerosis_2025_119136
crossref_primary_10_1016_j_ahjo_2025_100560
crossref_primary_10_1186_s12944_025_02600_y
crossref_primary_10_1111_ene_16501
crossref_primary_10_4330_wjc_v17_i9_110278
crossref_primary_10_1146_annurev_pharmtox_090123_010552
crossref_primary_10_3389_fphar_2025_1528671
crossref_primary_10_1016_j_cca_2025_120581
crossref_primary_10_3389_fendo_2025_1610884
crossref_primary_10_3390_life14111403
crossref_primary_10_24884_1609_2201_2025_104_1_32_43
crossref_primary_10_3390_jcdd12050169
crossref_primary_10_1002_clc_70066
crossref_primary_10_3390_biomedicines11123289
crossref_primary_10_1080_07853890_2025_2555520
crossref_primary_10_1016_j_acvd_2024_07_061
crossref_primary_10_1097_CRD_0000000000001017
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1146/annurev-pharmtox-031023-100609
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1545-4304
ExternalDocumentID 37506332
Genre Journal Article
Review
GroupedDBID ---
-QD
-QH
0R~
1KX
36B
39C
4.4
51A
5FA
5FB
5FC
5FD
5FE
5FF
7A.
85S
AABJL
AAGWO
AALHT
AALUV
AAOHI
AAQMF
AARJV
AAWJP
AAXSQ
AAYIS
AAYJJ
ABDOG
ABGRM
ABIPL
ABJNI
ABKGM
ABVYV
ABZNY
ACAHA
ACDVT
ACGFS
ACGOD
ACJYF
ACKHT
ACMXS
ACNCT
ACPHO
ACPRK
ACQCJ
ACRLM
ACSOE
ADHEY
ADLON
ADNJN
ADSVE
AEAIQ
AEKBM
AENEX
AEPIK
AFCZG
AFERR
AFKDQ
AFKEJ
AFONB
AHIXL
AHKZM
AHMBA
AHVNO
AICBU
AIDEK
AIJFW
AJAAW
ALAFQ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTJG
AOUBY
AQQLW
ATAUN
B9D
B9E
B9F
B9G
B9H
B9L
B9N
BCFVH
BJPMW
BMYRD
CGR
CUY
CVF
EBS
ECM
EIF
EMB
EST
F-Q
F-S
F-V
F-X
F-Y
F-Z
F5P
FIWKU
FIXEU
FMZAJ
FQMFW
FT0
FU.
FUEKT
FXG
GJQJI
GLOEX
GNDDA
GOAVI
GQXMV
H13
HZ~
J1V
L7B
NPM
O9-
RAR
RAV
WH7
X7N
YSK
ZYWBE
~KM
7X8
ACQLW
RIG
TUS
ID FETCH-LOGICAL-a443t-1b16db2d5d18d387018a9ed20d2811812243cef6b2167c0af822e60e1787acf12
IEDL.DBID 7X8
ISICitedReferencesCount 28
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001152744900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1545-4304
IngestDate Sun Sep 28 10:18:52 EDT 2025
Thu Apr 03 07:02:06 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords atherosclerosis
clinical trial
cardiovascular disease
lipoprotein(a)
therapy
antisense oligonucleotides
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a443t-1b16db2d5d18d387018a9ed20d2811812243cef6b2167c0af822e60e1787acf12
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.annualreviews.org/content/journals/10.1146/annurev-pharmtox-031023-100609
PMID 37506332
PQID 2854435563
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2854435563
pubmed_primary_37506332
PublicationCentury 2000
PublicationDate 2024-01-23
PublicationDateYYYYMMDD 2024-01-23
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-23
  day: 23
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Annual review of pharmacology and toxicology
PublicationTitleAlternate Annu Rev Pharmacol Toxicol
PublicationYear 2024
SSID ssj0009341
Score 2.5542753
SecondaryResourceType review_article
Snippet Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 135
SubjectTerms Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - genetics
Cholesterol, LDL - metabolism
Cholesterol, LDL - therapeutic use
Heart Disease Risk Factors
Humans
Lipoprotein(a) - genetics
Lipoprotein(a) - metabolism
Lipoprotein(a) - therapeutic use
Risk Factors
Title LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
URI https://www.ncbi.nlm.nih.gov/pubmed/37506332
https://www.proquest.com/docview/2854435563
Volume 64
WOSCitedRecordID wos001152744900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7eEF-8X-aNCDIUFmySNm19ERkOH-YousneStomMIR22inu33vSC2UvIvjSp5Y0yTknX05Ovg-hS9tIi8pIEKHBgm3XV0TyWBFXwm5CsUiogp3_te8OBt547AdVwi2vyirrmFgE6iSLTY78xtz0g6XdEfxu-k6MapQ5Xa0kNJbRKgcoYxzTHTds4T63S75U2yE27NvXUbtix61FXsjUEETPsm9iKDKZKdOyhPUL3CyWnd7Wf394G21WgBPflxayg5ZUuovaQclYPe_gYXMBK-_gNg4aLuv5Hhr1gyt5fYtfCppZ6EsHG6Lq8uV6alWCuwtlrfh5kr91sEwTbJJeRgdpoZ19NOo9DLuPpFJiIBL6MCM0okZ3KnES6iUcXJx60lcJsxLmmZurgANggrWIGBVubEkNsEMJS1EIBzLWlB2glTRL1RHCUQwbPNdVWnnS9j3tUZfGkVSOjpXQ2mmhi3o4Q7B0c3whU5V95mEzoC10WM5JOC0pOUIOwEdwzo7_8PUJ2mCATEwehfFTtKrBz9UZWou_ZpP847wwIXgOgqcf0uXRcQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LP%28a%29%3A+Structure%2C+Genetics%2C+Associated+Cardiovascular+Risk%2C+and+Emerging+Therapeutics&rft.jtitle=Annual+review+of+pharmacology+and+toxicology&rft.au=Tasdighi%2C+Erfan&rft.au=Adhikari%2C+Rishav&rft.au=Almaadawy%2C+Omar&rft.au=Leucker%2C+Thorsten+M&rft.date=2024-01-23&rft.issn=1545-4304&rft.eissn=1545-4304&rft.volume=64&rft.spage=135&rft_id=info:doi/10.1146%2Fannurev-pharmtox-031023-100609&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-4304&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-4304&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-4304&client=summon